BALVERSA

• tagApproval44 co-mentions · 11 sources
• drugerdafitinib44 co-mentions · 11 sources
• companyJanssen Biotech Inc22 co-mentions · 11 sources
• tagSmall Molecule22 co-mentions · 11 sources

Trials studying BALVERSA

• phase2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Canceractive not recruitingn=239
• phase1A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Canceractive not recruitingn=5
• phase3A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrationsactive not recruitingn=629
• phase2Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancerrecruitingn=235
• phase2A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Canceractive not recruitingn=125
• phase2A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterationsactive not recruitingn=316
• phase2A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)completedn=107
• phase2Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterationsrecruitingn=90